ESMO 2021 Roundup

Bookmark and Share
Published: 22 Sep 2021
Views: 2303
Rating:
Save
Dr Bishal Gyawali - Queen's University, Kingston, Canada

Dr Bishal Gyawali speaks to ecancer following ESMO 2021 about the highlights from this year’s conference.

Dr Gyawali discusses presentations that cover several areas of cancer including genitourinary, urothelial, breast, cervical, head and neck, GI and lung, including adjuvant immunotherapy, negative and single-arm trials.

Some of the trials he refers to are:

STAMPEDE, PEACE-1, VESPER, BrighTNess, DESTINY, TULIP, KEYNOTE-355, KEYNOTE-826, KEYNOTE-716, IMpower010, AtezoTRIBE, NEONAX, Checkmate 649, and DESTINY-Lung01.
 

Genitourinary Cancers
STAMPEDE Trial
PEACE-1 Trial
Urothelial Cancers
VESPER Trial
Breast Cancer
BrighTNess Trial
GIM4 Trial
Metastatic Breast Cancer
DESTINYBreast03 study
TULIP trial
KEYNOTE-355 study
Cervical Cancer
KEYNOTE-826 study
Adjuvant Immunotherapy Trials
KEYNOTE-716 study
IMpower010 study
GI Cancers
AtezoTRIBE study
NEONAX trial
GASTRIPEC-I trial
CheckMate649 study
Head and Neck Cancers
GORTEC-REACH trial
Final results of CheckMate 651
Nasopharyngeal Carcinoma
Lung Cancer
DESTINY-Lung01 trial
Final Comments

All opinions expressed in this video are the speakers own and do not reflect that of any institution.